Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Dihydropyrimidine dehydrogenase, Internal medicine, Chemistry, KRAS, Panitumumab, and Cetuximab.
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis
Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity
Pronounced between‐subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers
Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of uracil and dihydrouracil in human plasma
Exploring the intracellular pharmacokinetics of the 5‐fluorouracil nucleotides during capecitabine treatment
Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele
A <i>let-7</i> microRNA-Binding Site Polymorphism in <i>KRAS</i> Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy
Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination